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Background
Methotrexate (MTX) which has been used for 20 years
in Juvenile Idiopathic Arthritis (JIA) has now become
the first-choice, second-line agent for children with
polyarticular course JIA. New biologic drugs are used
for MTX-failing patients and have been assessed in con-
trolled trials for effectiveness. Safety data of these drugs
are slowly and selectively emerging as post-marketing
data. For better efficiency of collecting these data a large
pharmacovigilance registry (PharmaChild) is being con-
structed supported by the European Union. This will
enable the pediatric rheumatologists to overlook the
whole spectrum of moderate to serious adverse events
of these newer drugs and hence to advise their patients
better on the effectiveness as well as the relative safety
of the newer agents. The patients treated with these
newer drugs need to be compared to the patients trea-
ted with MTX. To get a better understanding of all
adverse events already encountered in MTX-therapy in
JIA-patients we performed a meta-analysis.
Aim
To offer insight into the incidences of the adverse
events (AEs) due to treatment of JIA with MTX.
Methods
By using the MeSH terms ‘Arthritis Juvenile Rheumatoid’
and ‘Methotrexate’,P u b m e da n dr e f e r e n c el i s t so f
selected articles were searched. Trials were included if
patients fulfilled the diagnostic criteria for JIA, Juvenile
Rheumatoid Arthritis or Juvenile Chronic Arthritis and
when treated with MTX in doses of 2.5-40 mg/wk. Exclu-
sion criteria were MTX used for treatment of oncologic
disease or in combination with other DMARDs in the
majority of patients or treatment with biologicals.
Results
Twenty-six studies were identified. In total, 3984
patient-years of MTX-exposure in 2588 JIA-patients
were analyzed. A total of 1247 adverse events were
noted with an exposure-adjusted risk of 31.30% per 100
patient-years. The most common adverse events were
found in the liver (8.08%, mainly elevated liver enzyme
tests) and gastrointestinal events (7.23%, mainly nausea
or vomiting), followed by unspecified- (6.25%), infectio-
logic- (2.61%), skin- (2.56%), mucosal- (1.36%), hemato-
logic- (0.93%), neurologic- (0.90%), psychologic- (0.88%)
events. Serious adverse events were seen in 0.50%. Per
year of therapy MTX was temporarily discontinued in
1.26%, permanently withdrawn in 0.80% and discontin-
ued unspecified in duration in 1.10%.
Conclusion
In general, children with JIA tolerate MTX well. More
than two-thirds of patients do not have any adverse
events when treated with MTX for 1 year. The most
common side effects are mild and related to elevated
liver enzyme tests and nausea or vomiting. Infectiologic
side effects were mentioned in only 2.61%. The risk of a
s e r i o u sa d v e r s ee v e n td u et oM T Xi s1i ne v e r y2 0 0
patients treated for 1 year. MTX discontinuation (tem-
porarily or permanent) due to adverse events was neces-
sary in less than 5% per treated year.
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